current treatment challenges of io refractory patients

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Therapeutic approaches such as surgery, radiation therapy, and chemotherapy form the conventional methods of combating cancers and are still the mainstays of cancer treatment; however, the recent emergence of immunotherapies, targeted therapies has also played an instrumental role in decreasing the cancer burden.

Immunotherapy has the potential to enable long-lasting immunity against cancer cells and increasing survival expectations. Extensive genomic studies have facilitated the identification of molecular biomarkers that directed the beginning of targeted therapies. The management of immune-oncology (IO)-refractory patients presents a significant challenge in modern cancer treatment. While immune checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies have revolutionized cancer care by producing durable responses in several malignancies, many patients either fail to respond from the outset (primary resistance) or relapse after an initial response (acquired resistance). Addressing treatment challenges in this subset of patients is crucial for advancing oncology.

Immuno-oncology (I-O) therapeutics, despite yielding effective outcomes, remain associated with unpredictable outcomes with a risk of failure and adverse side-effects.

Through the white paper, DelveInsight aims to highlight the major therapy approaches with an exclusive focus on the current and future aspects of Immuno-oncology (I-O) therapeutics and the recent highlights and key developments in the field